Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Repligen

Indexes Keep Rising While Oil Sinks; Apple Unveils New Products At 'Far Out' Event

The Dow Jones traded higher while the Nasdaq led the upside. Apple unveiled new products at 'Far Out' product launch.

Investors Business Daily

Stock Market Near Session Highs At Midday; IBD 50 Index Lags

Stock Market Near Session Highs At Midday; IBD 50 Index Lags

The market is trading positive after futures indicated a down day. Solar stocks soared.

Investors Business Daily

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review

The stock market rally had mixed action, with the Nasdaq and small caps rising while the S&P 500 and oil prices fell.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Biotech Leader Can't Stop Growing

Repligen is doing a marvelous job exploiting its niche in the biotech ecosystem.

Repligen's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, Repligen (NASDAQ:RGEN) earned $46.96 million, a 61.33% increase from the preceding quarter. Repligen also posted a total of $206.40 million in sales, a 10.66% increase since Q4.

Recap: Repligen Q1 Earnings

Repligen (NASDAQ:RGEN) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Repligen Earnings Conference Call Is Coming Up, Here's What You Need To Know

Repligen (NASDAQ:RGEN) will host a conference call at 08:30 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. How to Attend Repligen (RGEN) Conference Call Follow this link to access the live webcast.

inkl

Read news from The Economist, FT, and more,
with one subscription

Repligen Earnings Perspective: Return On Capital Employed

Repligen Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Repligen (NASDAQ:RGEN) showed a loss in earnings since Q3, totaling $29.11 million. Sales, on the other hand, increased by 4.66% to $186.52 million during Q4.

Repligen's Q4 Earnings Beat Expectations, Issues Solid FY22 Guidance

Repligen's Q4 Earnings Beat Expectations, Issues Solid FY22 Guidance

Repligen Corp (NASDAQ: RGEN)

This Foreboding Sign Looms Over Repligen's Chart

This Foreboding Sign Looms Over Repligen's Chart

If history is any guide, there may be trouble ahead for shares of Repligen (NASDAQ:RGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

235,108 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play